American College of Clinical Pharmacy
      Search      Cart
         

ACCP Report - August 2019

Lockman, Karnes, and Dunnenberger to Receive ACCP Honors


ACCP members Kashelle Lockman, Jason Karnes, and Henry (Mark) Dunnenberger IV were selected by the 2019 ACCP Awards Committee to receive the College’s prestigious 2019 New Educator, New Investigator, and New Clinical Practitioner awards, respectively. The awards will be presented in New York, New York, on Sunday, October 27, 2019, during the Awards and Recognition Ceremony of the 2019 ACCP Annual Meeting.

The ACCP New Educator Award is given to recognize and honor a new educator for outstanding contributions to the discipline of teaching and to the education of health care practitioners. The awardee must have been a Full Member of ACCP at the time of nomination and a member at any level for a minimum of 3 years; in addition, the awardee must have completed his or her terminal training or degree less than 6 years previously. Kashelle Lockman, Pharm.D., M.A., is a clinical assistant professor of internal medicine at the University of Iowa Carver College of Medicine, a clinical assistant professor in hospice and palliative care at the University of Iowa College of Pharmacy, and a clinical pharmacy specialist in palliative care at the University of Iowa Hospitals and Clinics. Lockman received her Pharm.D. degree from the University of Maryland School of Pharmacy, and completed postgraduate training there, specializing in geriatrics and palliative care.

During her postgraduate experience at the University of Maryland, she was recognized as an exceptional and engaging role model to students and trainees. University of Mississippi Professor Stuart Haines wrote in his letter of nomination,

Dr. Lockman invited me to collaborate with her and Dr. Mary Lynn McPherson on her major Fellowship project, which formally evaluated the learning outcomes associated with a “flipped classroom” model. The research was exceptionally well designed and executed…. The study compared outcomes to a historical control as well as other content concurrently taught using a traditional-teacher centered model of instruction. In short, this was a rigorous, sophisticated study which Dr. Lockman designed and executed. The research report was published as a featured article in Academic Medicine – the official journal of the American Association of Medical Colleges and the highest ranking (in terms of citations and influence) educational journal in the biomedical sciences. For health professions educators, this is like hitting a home run in the World Series in your rookie year…. Dr. Lockman understands that teaching is not the outcome of interest – it is merely the means. She is more interested in learning and student success. She eschews teacher-centered approaches and seeks to empower learners. Although she could easily be the sage on the stage, she’s chosen to be the guide on the side whose passion and caring attitude enable students, residents, and colleagues to go beyond what they thought possible. To me, that’s an educator’s highest calling.

Lockman has received the Andrew G. DuMez Award for Superior Proficiency in Pharmacy, the University of Maryland School of Pharmacy Leadership Award, and the University of Maryland Geriatrics and Gerontology Education and Research Program Award for Excellence in Geriatric Pharmacy. She has published her research in peer-reviewed journals, including the American Journal of Hospice and Palliative Medicine, Journal of Palliative Care, American Journal of Physiology: Heart and Circulatory Physiology, and Academic Medicine.

The New Investigator Award recognizes an ACCP member who has made a significant impact on an aspect of clinical pharmaceutical science. The awardee must have been a member of ACCP for more than 3 years, must have completed his or her terminal training or degree less than 6 years previously, and must have a research program with a substantial publication record that includes a programmatic theme or an especially noteworthy single publication. Jason Karnes, Pharm.D., Ph.D., BCPS, FAHA, is the director of scientific programs at the University of Arizona and an alternate member of the institutional review board for the University of Arizona Human Subjects Protection Program. He received his Pharm.D. degree and his Ph.D. degree in clinical pharmaceutical sciences from the University of Florida and completed a 3-year research fellowship at Vanderbilt University School of Medicine, Division of Clinical Pharmacology in Nashville, Tennessee. Karnes’ research is focused on leveraging genetics to predict and prevent adverse reactions to cardiovascular drugs, including heparin-induced thrombocytopenia (HIT) and thiazide-induced diabetes. At the time of his nomination, he had published more than 30 papers in the peer-reviewed literature, including first-author publications in high-impact journals such as Pharmacotherapy, Science Translational Medicine, and Pharmacogenomics.

Dan Roden, M.D., professor of medicine, pharmacology, and biomedical informatics and senior vice president for personalized medicine at Vanderbilt University, commented on Karnes’ qualifications for the New Investigator Award in his letter of support:

During his fellowship, Jason conducted a high-quality and productive series of studies aimed at understanding the genetic underpinnings of HIT. During his fellowship, Jason served as the Chief Fellow in the Division of Clinical Pharmacology and received the Vanderbilt Clinical Pharmacology Fellows Teaching Award. Jason subsequently led an effort to assemble multiple international cohorts in order to perform a well-powered genome-wide association study (GWAS) for HIT. Jason managed these collaborations expertly and we are in the process of submitting a manuscript describing our collaborative work. Jason has been the primary driver of this important research into the genomics of HIT. It is clear to me that Jason has the leadership and social skills to collaborate successfully and he shows fantastic potential to continue working with multiple investigators across departments, institutions, and countries. I have been extremely impressed by the quality of Jason’s research, which is marked by in-depth pharmacogenomics expertise, determination for acquiring quality data, and creative and technical insights that have improved ongoing projects. Jason is in an excellent position to make a vertical leap in determining predictive biomarkers to prevent adverse reactions to cardiovascular drugs. Jason is the first author on our Science Translational Medicine paper that examined disease associations of human leukocyte antigen (HLA) alleles using our PheWAS approach. This manuscript adds to an already impressive record of high-quality publications…. In summary, Jason has an extremely strong scientific background and a significant publication record in the field of cardiovascular pharmacogenomics. He has my full, enthusiastic support in his nomination for the ACCP New Investigator Award.

Joe Garcia, M.D., Dr. Merlin K. DuVal Professor of Medicine at the University of Arizona Health Sciences, added in his letter of nomination:

Upon completion of his fellowship training with Dr. Dan Roden at Vanderbilt University in 2015, Jason was recruited to the University of Arizona as a junior faculty (tenure-eligible) in the Department of Pharmacy Practice and Science at the UA College of Pharmacy to continue and extend his research in cardiovascular pharmacogenomics. When Jason expressed interest in joining my critical care research group, with his training in epidemiology and clinical research background, I was excited to provide this training experience in our research program. In the past 2 years, Jason has immersed himself in translational research with a focus on studying the genetic and transcriptomic factors associated with HIT. Jason has demonstrated a very strong published record of accomplishments, publishing in high-impact journals and publishing the first genome-wide association study (GWAS) for HIT as first author. Despite a very steep learning curve, Jason has been remarkably productive with his research endeavors. In the past 24 months, he has published 6 first or last author original publications and coauthored many more. Recently, Jason and I have co-authored a manuscript identifying genomic risk factors for Acute Respiratory Distress Syndrome (ARDS) which was published in Am J Respir Crit Care Med. Jason and I also co-authored an abstract describing a vasodilator responsiveness GWAS in pulmonary arterial hypertension that is accepted by the American Heart Association (AHA) as a late-breaking abstract. Jason’s research efforts in HIT are bolstered by an AHA Scientist Development Grant, on which I am a mentor, and a Futures Grant from the American College of Clinical Pharmacy. He is also a recipient of the NIH Loan Repayment Program from the NHLBI, on which I am a mentor, and is one of eight recipients of an intramural grant program, the UA Health Science Career Development Award. Recently, Jason received an impact score of 18 on his NIH K01 award application and he is poised to receive NIH funding for his work related to HIT. These awards underscore Jason’s unwavering commitment to an academic research career and highlight his potential to secure extramural funding. Jason has shown dedication, motivation, and a strong commitment to translational pharmacogenomics research and leaves little doubt that he has the “right stuff” for a career as an impactful research scientist.

Karnes will deliver the annual New Investigator Award lecture during the October 27 Awards and Recognition Ceremony.

The New Clinical Practitioner Award honors a new clinical practitioner who has made outstanding contributions to the health of patients and/or the practice of clinical pharmacy. The awardee must have been a Full Member of ACCP at the time of nomination, as well as a member at any level for a minimum of 3 years; in addition, the awardee must have completed his or her terminal training or degree less than 6 years previously. Henry (Mark) Dunnenberger IV, Pharm.D., BCPS, serves as the director of pharmacogenomics in the Center for Molecular Medicine for the NorthShore University HealthSystem in Evanston, Illinois.

Kelly Caudle, Pharm.D., Ph.D., BCPS, CPIC, director of St. Jude Children’s Research Hospital, wrote in her letter of support,

The pharmacogenomics clinic at NorthShore University HealthSystem was created by Dr. Dunnenberger and his team in March 2015. This is the longest-running dedicated pharmacogenomics clinic in the country. The clinic was created in response to a community need to use pharmacogenomics data to guide drug selection. The goals of the clinic are to ensure responsible and prudent use of pharmacogenomics testing, meet the clinical pharmacogenomics needs of patients and providers, and gain a better understanding of how patients and providers want to interact with pharmacogenomics data. There have been 631 patient visits, accounting for 434 patients, in the clinic during March 2015 to November 2017. Pharmacists have used results from the clinic across the system including anticoagulation clinic, oncology outpatient clinic, and psychiatric inpatient unit. This is possible because of the electronic health record (EHR) integration of pharmacogenomics data generated in the clinic by Dr. Dunnenberger. Because educational materials are lacking in this area, Mark developed cases from the clinic that have been used as educational examples to help clinicians better understand how pharmacogenomics data can be applied in care. These cases have reduced confusion for clinicians and increased utilization of pharmacogenomics data to optimize pharmacotherapy. As more clinicians want to use pharmacogenomics data but have limited clinic capacity, Dr. Dunnenberger had to develop new mechanisms for testing patients across the system. Now, any clinician can order testing for a patient, and the results are integrated into the EHR and presented in routine clinical workflows with additional education resources. This system has been live since November 2016 and led to over 450 patients being tested. More than 98% of patients testing at NorthShore have had an actionable result which may result in a change in drug therapy. Dr. Dunnenberger’s clinic has been a model for at least three other health systems starting pharmacogenomic clinics: Mission Health, Minnesota Children’s hospitals and clinic, and UF health. The clinic is an early entry point for supporting personalized medicine and utilizes the unique skill set of pharmacists. Mark also has on-going implementation development projects in Egypt and Taiwan. Although the utility of pharmacogenetics has been documented over and over again, there has been a slow uptake of pharmacogenetics into clinic for numerous reasons. Dr. Dunnenberger thought creatively and was able to convince hospital administration that this clinic and service were vital to this health care system.

Roseann Gammal, Pharm.D., BCPS, assistant professor of pharmacy practice at the MCPHS University School of Pharmacy, commented in her letter of support:

Dr. Dunnenberger is as outstanding a role model as he is a clinical leader. It is difficult to create a clinical service, but to do it successfully without models developed by others is very impressive. Dr. Dunnenberger’s innovative service has not only filled a need but also will continue to serve as a model for others, as it has done for me. His willingness to share his experiences (both good and bad) and implementation model with others is truly admirable. Based on Dr. Dunnenberger’s clinical practice accomplishments, he would be an outstanding recipient of this award. I enthusiastically support his nomination without reservation.

Dunnenberger has been actively involved in ACCP and is also engaged in scholarship. At the time of his nomination, he had published 19 original articles and presented often at national and international meetings, including those of ACCP, the American Medical Informatics Association, the Precision Medicine World Conference, the Taipei Medical University College of Pharmacy, and the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Members of the 2019 ACCP Awards Committee who reviewed and evaluated the nominations for these awards were Bradley Phillips (chair), Mary Amato (vice chair), Melody Berg, Kelly Caudle, Brandon Dionne, Candice Garwood, Ila Harris, Kristi Kelly, Tyree Kiser, Christina Madison, Christopher Paciullo, and Chasity Shelton.